BioCryst’s oral BCX7353 meets primary endpoint in phase 3 APeX-2 trial
BioCryst announced the randomized, double-blind, placebo-controlled, Phase 3 APeX-2 trial of once-daily, oral BCX7353 for prevention of hereditary angioedema attacks achieved its primary endpoint for both dose levels (110 mg and 150 mg), with the 150 mg dose reducing the attack rate in HAE patients. May 21, 2019